Strides Pharma Science Ltd Sees Mixed Technical Signals Amid Price Momentum Shift

Price Momentum and Recent Market Performance

On 1 Feb 2026, Strides Pharma Science Ltd (NSE: 688428) closed at ₹877.00, marking an impressive day change of 8.41% from the previous close of ₹808.95. The stock’s intraday range was wide, with a low of ₹792.60 and a high of ₹908.00, indicating heightened volatility and strong buying interest. This surge contrasts with the broader market, as the Sensex recorded a modest 0.90% gain over the past week, while Strides outperformed with a 10.15% weekly return.

However, the stock’s one-month return stands at -3.60%, slightly worse than the Sensex’s -2.84%, signalling some short-term pressure. Year-to-date, Strides has declined by 2.81%, marginally underperforming the Sensex’s 3.46% drop. Over longer horizons, the stock has delivered robust gains, with a 34.24% return over the past year and an extraordinary 511.40% over three years, far outpacing the Sensex’s 7.18% and 38.27% respectively. This long-term outperformance underscores the company’s growth trajectory despite recent technical challenges.

Technical Trend Shift: From Mildly Bearish to Sideways

Technical analysis reveals a subtle but important shift in Strides Pharma’s trend dynamics. The overall technical trend has moved from mildly bearish to sideways, suggesting a pause or consolidation phase rather than a clear directional move. This is corroborated by the Bollinger Bands indicator, which shows sideways movement on the weekly chart and a mildly bullish stance on the monthly chart, indicating reduced volatility and potential for a breakout.

The daily moving averages have turned mildly bullish, with the stock price currently trading above key short-term averages. This suggests that recent buying momentum is gaining traction, although the absence of strong confirmation from other indicators tempers enthusiasm.

MACD and KST Indicators Signal Caution

The Moving Average Convergence Divergence (MACD) indicator remains mildly bearish on both weekly and monthly timeframes. This suggests that despite recent price gains, the underlying momentum has not fully shifted to a bullish phase. The MACD histogram and signal lines indicate that the stock is yet to generate a strong buy signal, reflecting lingering selling pressure or consolidation.

Similarly, the Know Sure Thing (KST) oscillator aligns with this cautious outlook, showing mildly bearish readings on weekly and monthly charts. The KST’s sensitivity to price momentum changes implies that the recent rally may be a corrective bounce rather than a sustained uptrend.

RSI and OBV: Neutral to Mildly Bearish Signals

The Relative Strength Index (RSI) on weekly and monthly charts currently offers no clear signal, hovering in neutral territory. This indicates that the stock is neither overbought nor oversold, consistent with the sideways trend interpretation. Investors should watch for any RSI divergence or movement beyond the 70/30 thresholds for clearer directional cues.

On-Balance Volume (OBV), a volume-based indicator, remains mildly bearish on both weekly and monthly timeframes. This suggests that volume trends have not yet confirmed the recent price strength, implying that the rally may lack robust institutional support at this stage.

Dow Theory and Moving Averages: Mixed Messages

Dow Theory assessments on weekly and monthly charts continue to reflect a mildly bearish stance, signalling that the broader market sentiment for Strides Pharma remains cautious. However, the daily moving averages’ mildly bullish position offers a counterpoint, highlighting short-term optimism among traders.

This divergence between short-term bullishness and longer-term caution underscores the importance of monitoring upcoming price action and volume trends closely. A decisive break above the 52-week high of ₹1,024.90 could confirm a bullish breakout, while failure to sustain current levels may lead to renewed selling pressure.

Valuation and Market Capitalisation Context

Strides Pharma’s current market capitalisation grade stands at 3, reflecting a mid-cap status within the Pharmaceuticals & Biotechnology sector. The company’s Mojo Score has recently deteriorated to 46.0, resulting in a downgrade from Hold to Sell on 19 Jan 2026. This rating change reflects the mixed technical signals and the need for caution amid uncertain momentum.

Investors should weigh these technical factors alongside fundamental considerations, including the company’s product pipeline, regulatory environment, and sector dynamics, before making investment decisions.

Investor Takeaway: Navigating a Complex Technical Landscape

Strides Pharma Science Ltd’s recent price momentum shift and mixed technical signals present a nuanced picture for investors. The stock’s strong intraday gains and mildly bullish daily moving averages suggest emerging optimism, yet the persistence of mildly bearish MACD, KST, and OBV indicators on longer timeframes counsel caution.

With the RSI neutral and Bollinger Bands indicating sideways movement, the stock appears to be consolidating after a period of volatility. This phase could precede either a breakout or a retracement, making it imperative for investors to monitor volume trends and key resistance levels closely.

Long-term investors may find reassurance in the stock’s impressive multi-year returns, which have significantly outpaced the Sensex. However, the recent downgrade to a Sell rating by MarketsMOJO reflects the current technical uncertainties and the need for a more definitive trend confirmation before committing fresh capital.

In summary, Strides Pharma Science Ltd is at a technical crossroads. Short-term traders might capitalise on momentum swings, while long-term holders should remain vigilant for signs of trend confirmation or reversal. The evolving technical landscape underscores the importance of a balanced approach combining technical analysis with fundamental insights in the Pharmaceuticals & Biotechnology sector.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →